Clinical Trial: Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1

U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07598643) titled 'Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1' on May 13.

Brief Summary: This protocol describes a phase 2, double-blind, randomized, placebo-controlled clinical trial for Janus kinase (JAK) inhibition in Down syndrome (DS). This trial will evaluate the safety and efficacy of a 6-month treatment with the JAK1/3 inhibitor tofacitinib (XELJANZ) in individuals ages 6-22 (inclusive) with DS. There will be two main arms for this study: a treatment arm and a placebo control arm. Participants will be randomized into the treatment or placebo arm. Those completing 6 months in the placebo arm m...